澳洲保健品Swisse女士复合维生素(120片瓶)说明书

swisse liver detox用法
Swisse Liver Detox是一种能够帮助肝脏排毒的保健品。

它含
有多种天然成分，包括乳薊提取物、水飞蓟、甘草和小卫矛等。

使用方法如下：
1. 每日成人服用1-2片，与饭后用水一同服用。

2. 不建议孕妇、哺乳期妇女和儿童使用。

3. 请在使用之前仔细阅读并遵循产品包装上的说明。

4. 如有任何持续性症状或对该产品成分过敏的情况，请咨询医生。

重要提示：
1. 本产品不能代替均衡的饮食。

2. 饮食习惯和生活方式对于肝脏健康至关重要。

3. 如果您有任何肝脏疾病或正在服用其他药物，请在使用之前咨询医生。

4. 如果您正在接受医疗过程，请在使用之前咨询医生。

总结而言，使用Swisse Liver Detox时应按照产品包装上的说
明进行，并在使用之前咨询医生以确保其安全和适合性。

复合维生素片说明书作用批准文号：国药准字J20210155生产厂家：Bayer S.A.药品说明书【主要成分】本品为复方制剂，每片含： 12种维生素...【功能主治】本品用于妊娠期和哺乳期妇女对维生素、矿物质和微量元素的额外需求;并预防妊娠期因缺铁和叶酸所致的贫血。

【用法用量】本品口服。

一次1片，一日1次，与早餐同时服用;如存在晨起恶心现象，可在中午或晚上服用。

【不良反应】1. 本品耐受性良好，少数病例会出现胃肠道功能紊乱如便秘，但一般不须停药。

某些敏感的妇女可能会出现一定程度的过度兴奋，故此类病人避免在晚间服用。

2. 如出现任何不良事件或反应，请咨询医师。

【禁忌症】1. 高维生素A血症、高维生素D血症、高钙血症、高钙尿症者禁用。

2. 肾功能不全、铁蓄积、铁利用紊乱者禁用。

【剂型】片剂注意事项：1. 本品不推荐儿童使用。

2. 请严格按推荐剂量服用。

3. 可是粪便颜色变黑，但无临床意义。

4. 对本品过敏者禁用，过敏体质者慎用。

5. 本品性状发生改变时禁止使用。

6. 请将本品放在儿童不能接触的地方。

7. 如正在使用其他药品，使用本品前请咨询医师或药师。

成份：本品为复方制剂，每片含：12种维生素7种矿物质和微量元素1、维生素A 4,000国际单位1.2毫克;钙 0.125克。

2、维生素B 11.6毫克;镁 0.1克。

3、维生素B 21.8毫克;磷 0.125克。

4、维生素B 62.6毫克;铜 1毫克。

5、维生素B 24.0微克;铁 60毫克。

6、维生素C 0.1克;锰 1毫克。

7、维生素D3 500国际单位12.5微克;锌 7.5毫克。

8、维生素E 15毫克。

9、生物素 0.2毫克。

10、叶酸 0.8毫克。

11、烟酰胺 19毫克。

12、泛酸钙 10毫克。

作用类别：本品为维生素及矿物质类非处方药药品。

药物相互作用：1. 不宜与四环素类药物同用。

必要时两药须间隔两小时以上分别服用。

2. 不宜与其他含维生素A和维生素D的药物同用。

swisse liver detox用法摘要：1.Swisse Liver Detox 产品简介2.Swisse Liver Detox 的主要成分3.Swisse Liver Detox 的使用方法4.Swisse Liver Detox 的功效及适用人群5.Swisse Liver Detox 的注意事项6.总结正文：Swisse Liver Detox 是一款肝脏排毒产品，旨在帮助身体清除毒素，提高肝脏功能。

本篇文章将详细介绍Swisse Liver Detox 的用法、成分、功效及注意事项等内容。

1.Swisse Liver Detox 产品简介Swisse Liver Detox 是一款澳大利亚品牌Swisse 推出的肝脏排毒产品。

本产品采用天然成分，无添加糖分、人造香料及色素，适用于希望改善肝脏功能、提高身体排毒能力的人群。

2.Swisse Liver Detox 的主要成分Swisse Liver Detox 的主要成分包括：朝鲜蓟、奶蓟草、姜黄、胡椒薄荷、荨麻、山楂和葡萄籽提取物。

这些成分均具有抗氧化、抗炎、保护肝脏等功能，共同协作以达到肝脏排毒的效果。

3.Swisse Liver Detox 的使用方法Swisse Liver Detox 的使用方法非常简单。

首先，请确保每天饮用足够的水，以便帮助身体排毒。

然后，每天早晨空腹服用两粒Swisse Liver Detox 胶囊。

建议持续使用8 周，以达到最佳效果。

在使用过程中，如遇到不适，请及时停止使用并咨询专业医生。

4.Swisse Liver Detox 的功效及适用人群Swisse Liver Detox 具有以下功效：- 帮助肝脏清除毒素，减轻肝脏负担- 抗氧化，保护肝脏细胞- 提高肝脏功能- 缓解酒后不适适用人群包括：- 长期饮酒者- 饮食不规律者- 经常熬夜者- 生活压力大者- 有肝脏疾病家族史者5.Swisse Liver Detox 的注意事项在使用Swisse Liver Detox 时，请注意以下事项：- 本产品不适合孕妇、哺乳期妇女及儿童使用- 患有疾病者在使用前请咨询医生- 若出现不适，请停止使用并咨询医生- 请存放于阴凉干燥处，避免阳光直射综上所述，Swisse Liver Detox 是一款有助于肝脏排毒的产品，适用于希望改善肝脏功能的人群。

UnitedHealthcare ® Community PlanViltepso ® (Viltolarsen)Policy Number : CS2023D0095KEffective Date : September 1, 2023 Instructions for Use Table of Contents Page Application ..................................................................................... 1 Coverage Rationale ....................................................................... 1 Applicable Codes .......................................................................... 2 Background ................................................................................... 2 Clinical Evidence ........................................................................... 3 U.S. Food and Drug Administration ............................................. 4 References ..................................................................................... 4 Policy History/Revision Information ............................................. 5 Instructions for Use ....................................................................... 5 This Medical Benefit Drug Policy does not apply to the states listed below; refer to the state-specific policy/guideline, if noted: State Policy/Guideline FloridaRefer to the state’s Medicaid clinical policy KansasNone LouisianaRefer to the state’s Medicaid clinical policy New JerseyViltepso ® (Viltolarsen) (for New Jersey Only) North CarolinaNone OhioViltepso ® (Viltolarsen) (for Ohio Only) PennsylvaniaViltepso ® (Viltolarsen) (for Pennsylvania Only) TexasRefer to drug-specific criteria found within the Texas Medicaid Provider Procedures ManualViltepso (viltolarsen) may be covered for the treatment of Duchenne muscular dystrophy (DMD) in patients who meet all of the following criteria :• For initial therapy , all of the following:o Diagnosis of Duchenne muscular dystrophy by, or in consultation with, a neurologist with expertise in the diagnosis of DMD; and o Submission of medical records (e.g., chart notes, laboratory values) confirming the mutation of the DMD gene is amenable to exon 53 skipping; ando One of the following: ▪ Submission of medical records (e.g., chart notes, laboratory values) confirming that the patient has a 6-MinuteWalk Test (6MWT) ≥ 300 meters while walking independently (e.g., without side-by-side assist, cane, walker,wheelchair, etc.) prior to beginning Viltepso therapy; or▪ Both of the following:Commercial Policy • Viltepso ® (Viltolarsen)Submission of medical records (e.g., chart notes) confirming that the patient is ambulatory without needing anassistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.); and o One of the following:▪Patient has achieved a score of greater than 17 on the North Star Ambulatory Assessment (NSAA); or▪Patient has achieved a time to rise from the floor (Gower’s test) of less than 7 seconds;ando Viltepso is prescribed by, or in consultation with, a neurologist with expertise in the treatment of DMD; ando Viltepso dosing for DMD is in accordance with the United States Food and Drug Administration approved labeling; and o Viltepso is not used concomitantly with other exon skipping therapies for DMD; ando Initial authorization will be for no more than 6 monthsFor continuation of therapy, all of the following:o Patient has previously received Viltepso; ando Viltepso is prescribed by, or in consultation with, a neurologist with expertise in the treatment of DMD; ando Submission of medical records (e.g., chart notes) confirming that the patient is ambulatory without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.); ando Viltepso dosing for DMD is in accordance with the U.S. Food and Drug Administration (FDA) approved labeling; and o Viltepso is not used concomitantly with other exon skipping therapies for DMD; ando Reauthorization will be for no more than 12 monthsViltepso will not be covered for other forms of muscular dystrophy.The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.HCPCS Code DescriptionJ1427 Injection, viltolarsen, 10 mgDiagnosis Code DescriptionG71.01 Duchenne or Becker muscular dystrophyDuchenne muscular dystrophy (DMD) is an X-linked disease that affects 1 in 3,600-6,000 live male births. DMD occurs as a result of mutations (mainly deletions) in the dystrophin gene. These mutations lead to an absence or a defect of the protein, dystrophin, resulting in progressive muscle degeneration, leading to loss of ambulation and additional respiratory, orthopedic, and cardiac complications. If left untreated, mean age of death is approximately 19 years of age.2-4Viltolarsen is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer (PMO) subclass. PMOs are synthetic molecules in which the five-membered ribofuranosyl rings found in natural DNA and RNA are replaced by a six-membered morpholino ring. Each morpholino ring is linked through an uncharged phosphorodiamidate moiety rather than the negatively charged phosphate linkage that is present in natural DNA and RNA. Each phosphorodiamidate morpholino subunit contains one of the heterocyclic bases found in DNA (adenine, cytosine, guanine, or thymine).1Viltolarsen is designed to bind to exon 53 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping. Approximately 8% of DMD patients have out of frame deletion mutations amenable to exon 53 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein.1Eteplirsen (Exondys 51) was the first PMO approved by the U.S. Food and Drug Administration for treatment of DMD patients with confirmed genetic mutations amenable to exon 51 skipping. Approximately 13% of DMD patients have out of frame deletion mutations amenable to exon 51 skipping. This indication was approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with eteplirsen. A clinical benefit of eteplirsen has not been established. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.5Golodirsen (Vyondys 53) was the second PMO approved by the US Food and Drug Administration for treatment of DMD patients with confirmed genetic mutations amenable to exon 53 skipping, the same population as viltolarsen. Approximately8-10% of DMD patients have out of frame deletion mutations amenable to exon 53 skipping. This indication was also approved under accelerated approval based on an increase in dystrophin in skeletal muscle.6Casimersen (Amondys 45) is an antisense oligonucleotide that is designed to bind to exon 45 of dystrophin pre-messenger RNA, resulting in exon 45 skipping during messenger RNA processing in patients with amenable deletion mutations of the DMD gene. The FDA granted accelerated approval of casimersen for the treatment of patients with DMD who have a confirmed mutation of DMD that is amenable to exon 45 skipping, which is thought to cause approximately 8 percent of DMD cases.14Viltolarsen is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.1A phase II study evaluated two doses of viltolarsen in 16 ambulatory boys aged 4 to 9 years with a DMD diagnosis and DMD gene amenable to exon 53 skipping over 24 weeks. Ambulatory boys on a stable corticosteroid regimen for at least 3 months who could complete time to stand from supine, time to run/walk 10 m, and time to climb four stairs assessments were included. The study was a multicenter, two period dose-finding clinical trial. The first study period, which corresponded to the first 4 weeks of treatment following enrollment, was double-blinded and placebo-controlled. Participants in both dose cohorts were randomized 3:1 to receive viltolarsen or placebo. The second study period began at week 5 for each participant. During this period, all participants received viltolarsen according to their cohort dose for a 20-week open-label treatment. Primary study outcomes included safety, tolerability, and pharmacokinetics of low-dose (40 mg/kg per week) and high-dose (80 mg/kg per week) viltolarsen in ambulant boys with DMD. Efficacy was assessed based on change from baseline in dystrophin protein level (measured as % of the dystrophin level in healthy subjects, i.e., % of normal) at week 25. Muscle dystrophin production was assessed as protein production by Western blot for the primary study efficacy outcome and as dystrophin mRNA splicing on RT-PCR, dystrophin protein production by MS, and dystrophin localization by IF staining for secondary study efficacy outcomes. Additional secondary efficacy outcomes were gross motor skill assessments of timed function tests, including time to stand from supine, time to run/walk 10 m, time to climb four stairs, North Star Ambulatory Assessment, and 6-minute walk test as well as quantitative muscle testing. These outcomes were compared with a matched natural history control group from the Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS).In patients who received viltolarsen 80 mg/kg once weekly, mean dystrophin levels increased from 0.6% of normal at baseline to 5.9% of normal by week 25, with a mean change in dystrophin of 5.3% of normal levels (p = 0.01) as assessed by validated Western blot; the median change from baseline was 3.8%. All patients demonstrated an increase in dystrophin levels over their baseline values. As assessed by mass spectrometry, mean dystrophin levels increased from 0.6% of normal at baseline to 4.2% of normal by week 25, with a mean change in dystrophin of 3.7% of normal levels; the median change from baseline was 1.9%.Comparison of viltolarsen-treated participants with 65 age-matched and treatment matched natural history controls from CINRG DNHS suggested evidence of clinical benefit of viltolarsen treatment. Viltolarsen-treated participants showed improvement or stabilization of function over the 25-week period, whereas the CINRG DNHS external comparator group exhibited a decline in all timed function tests, except for time to climb four stairs. Velocity in the time to run/walk 10 m test significantly improved in viltolarsen-treated participants at weeks 13 and 25 compared with a decline in controls from CINRG DNHS (change at 25 weeks compared with baseline: viltolarsen, 0.23 m/s; control, −0.04m/s). The 6-minute walk test showed significant improvement at week 25 in viltolarsen treated participants, whereas results from CINRG DNHS controls declined over the same period (change at 25 weeks compared with baseline: viltolarsen, 28.9 m; control, −65.3 m). Significant improvements in time to stand from supine were observed (change at 25 weeks compared with baseline: viltolarsen, −0.19 s; control, 0.66 s). Velocity in the time toimprovement or stabilization, but the differences between viltolarsen treatment and external comparator controls were not significant. Measures of muscle strength by isometric testing showed no differences between viltolarsen-treated participants and the CINRG DNHS external comparator control group.7RACER53 is an ongoing 48-week, phase 3 double-blind, placebo controlled, randomized clinical trial that will evaluate the efficacy of viltolarsen in ambulatory DMD patients with out-of-frame deletion mutations amenable to skipping exon 53. The study will enroll 74 boys from 4 to 8 years of age with genotypically confirmed DMD on a stable dose of corticosteroids who can walk independently without assistive devices with a time to stand of less than 10 seconds. The primary endpoint is the change from baseline to week 48 in the time to stand. Secondary outcomes include the change in time to run/walk 10 meters, change in 6MWT, change in the NSAA, change in time to climb four steps, and change in muscle force contraction measured by dyanometry.8The SKIP-NMD trial of golodirsen is a U.S.-based, blinded, placebo-controlled, dose-escalation two-part Phase I/II RCT of male patients aged six to 15 years with a DMD diagnosis and DMD gene amenable to exon 53 skipping. Patients age 6 to 15 years with stable cardiac and pulmonary function, and on a stable dose of corticosteroids for at least six months were included. Additional inclusion criteria included a baseline six-minute walk test (6MWT) of greater than 250 m, a North Star Ambulatory Assessment (NSAA) score of greater than 17 or a rise time of less than 7 seconds. In part one, 12 patients were randomized to receive once-weekly intravenous infusions at escalating doses of 4, 10, 20, 30 mg/kg of golodirsen or matching placebo for 12 weeks. Part two consists of an open-label period of all patients from part one and 13 newly recruited patients who are receiving once-weekly infusions of 30 mg/kg of golodirsen for up to 168 weeks.Part one of the SKIP-NMD trial assessed safety and tolerability. In part two, the primary endpoints are change from baseline in 6MWT at 144 weeks and change in dystrophin protein levels at 48 weeks. Secondary endpoints include drug pharmacokinetics, change from baseline in FVC percent predicted, and change from baseline in dystrophin intensity at 144 weeks.At the time of pre-planned interim analysis, data from baseline and week 48 muscle biopsies, exon 53 skipping, and dystrophin localization were available for 25 patients on golodirsen. The study is ongoing, and results for the primary efficacy endpoint of 6MWT at week 144 are not yet available. Mean baseline of dystrophin in the trial was reported to be 0.095% of normal. At 48 weeks, the mean level of dystrophin had increased to 1.019% of normal resulting in an absolute increase of 0.918% of normal (p < 0.001). A clinically meaningful change in level of dystrophin has not yet been established in humans. As such, the clinical significance of these results is not clear. Among individual patients, dystrophin levels at week 48 ranged from 0.09% to4.30%.9-11ESSENCE is an ongoing 96-week, Phase 3, double-blind, placebo controlled, randomized clinical trial that will evaluate the efficacy of golodirsen and casimersen in DMD patients with out-of-frame deletion mutations amenable to skipping exon 53 and exon 45, respectively. The study will enroll 222 boys from 7 to 13 years of age with genotypically confirmed DMD and 6MWT ≥ 300 m and ≤ 450 m. The primary endpoint is the change from baseline to week 96 in 6MWT.12Viltolarsen or golodirsen have not been studied in DMD that is not amenable to exon 53 skipping, nor in other forms of muscular dystrophy (e.g., Becker muscular dystrophy).1,6This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.Viltepso is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with Viltepso. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.1.Viltepso [package insert]. Paramus, NJ; NS Pharma, Inc, March 2021.2.Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne musculardystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol; 2010 Jan; 9(1):77 93.3.Bushby K, Finkel R, Birnkrant DJ, et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 2:implementation of multidisciplinary care. Lancet Neurol; 2010 Jan; 9(2):177-189.4.Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis,and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol.2018;17(3):251-267. doi: 10.1016/S1474-4422(18)30024.5.Exondys 51 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc, January 2022.6.Vyondys 53 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc, February 2021.7.Clemens PR, Rao VK, Connolly AM, et al. Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne musculardystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. 2020; 26;77(8):1-10. doi:10.1001/jamaneurol.2020.2025.8.Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)https:///ct2/show/NCT04060199?term=viltolarsen&draw=2&rank=1. Accessed June 5, 2023.9.Frank DE, Mercuri E, Servais, L, et al. Golodirsen induces exon skipping leading to sarcolemmal dystrophin expression inpatients with genetic mutations amenable to exon 53 skipping. Poster presented at: Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics; April 2-6, 2019; Seattle, WA.10.Muntoni F, Frank DE, Morgan J, et al. Golodirsen induces exon skipping leading to sarcolemmal dystrophin expression inpatients with genetic mutations amenable to exon 53 skipping [abstract]. Neuromuscul Disord. 2018;28:S5. Abstract D01.11.Muntoni F, Frank DE, Sardone V, et al. SRP-4053 induces exon skipping leading to sarcolemmal dystrophin expression inDuchenne muscular dystrophy patients amenable to exon 53 skipping. Poster presented at: 22nd International Annual Congress of the World Muscle Society; October 3-7, 2017; Saint Malo, France.12.Study of SRP-4045 and SRP-4053 in DMD Patients (ESSENCE)https:///ct2/show/NCT02500381?term=golodirsen&cond=Duchenne+Muscular+Dystrophy&rank=3.Accessed June 5, 2023.13.Institute for Clinical and Economic Review (ICER). Deflazacort, eteplirsen, and golodirsen for Duchenne musculardystrophy: Effectiveness and value: Evidence Report. https:///wp-content/uploads/2020/10/Corrected_ICER_DMD-Final-Report_042222.pdf. April 22, 2022. Accessed June 5, 2023. 14.Amondys 45 [package insert]. Cambridge, MA; Sarepta Therapeutics, Inc.: March 2023.Date Summary of Changes09/01/2023 ApplicationLouisianaReplaced reference link to the state-specific policy version with instruction to refer to the state’sMedicaid clinical policySupporting InformationArchived previous policy version CS2023D0095JThis Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state, or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state, or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state, or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state, or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.。

复合维生素【药品名称】商品名称：复合维生素英文名称：decavitamin拼音全码：Fu he wei sheng su【主要成份】本品主要成份为复合维生素。

【性状】本品为【适应症/功能主治】1、用于维生素A缺乏症，如干眼病、夜盲症、角膜软化症和皮肤粗糙等，据称本品对预防上皮癌，食管癌的发生也有一定作用。

2.维生素B缺乏时影响机体的生物氧化，使代谢发生障碍。

表现为口角炎、唇炎、舌炎、眼结膜炎和阴囊炎等。

本品可用于防治上述疾病。

3.临床用于维生素C缺乏引起的坏血病、贫血、过敏性疾病、心肌炎、慢性肝炎、克山病及急慢性中毒等，并能促进创伤愈合。

4.临床用于防治维生素D缺乏引起的软骨病、佝偻病以及因缺乏维生素引起的低血钙，骨质疏松症，龋齿，手足搐搦症及甲状旁腺功能减退等。

5.临床用于缺乏维生素B所致的各种疾病。

如脚气病、糙皮病及食欲不振等的辅助治疗。

本药含有机体正常代谢所必需的多种维生素及微量元素，补充多种维生素、矿物质及微量元素，用于维生素和微量元素缺乏的预防。

参与体内糖类、氨基酸、脂肪代谢、用于维生素及微量元素缺乏症的治疗与预防。

【用法用量】幼雏每100公斤饲料中添加本品50克；育成鸡每100公斤饲料中添加本品80克；产蛋鸡每100公斤饲料中添加本品100克；种鸡每100公斤饲料中添加本品100克；生长猪体重5-10公斤，每100公斤饲料中添加本品44克，体重10-20公斤，每100 公斤饲料中添加本品35克，体重20-100公斤，每100公斤饲料中添加本品26克。

【适用范围】本品适用于雏鸡、育成鸡、产蛋鸡和乳猪、幼猪、育肥猪、奶牛、兔、狐狸、貉、貂、等畜禽及动物。

六．贮藏密闭、遮光、干燥处保存。

七．保质期十八个月。

汤臣倍健多种维生素片(女士)的说明书维生素和矿物质是体内必须品，这些微量元素在日常生活中可以通过食物中获取，但是如果出现了意外情况的话，人体会缺少某些维生素等必要的微量元素，对于人体的健康影响是比较大的。

目前出现了一种叫做汤臣倍健多种维生素片(女士)的维生素矿物质药物，该药物对于人体无任何副作用，它能有助于身体的健康。

【药品名称】通用名称：多种维生素片(女士)商品名称：汤臣倍健多种维生素片(女士)拼音全码：TangChenBeiJianDuoZhongWeiShengSuPian(NvShi)【主要成份】β-胡萝卜素321μg,维生素B20.75mg,维生素B121.31μg,维生素 D3.01μ等。

【适应症/功能主治】1.均衡补充女性所需的多种维生素、矿物质；2.独特的均匀释放营养素技术；3.精确配方，不含磷、铜。

【规格型号】1000mg*70s【用法用量】每日1次，每次1片。

建议饭后食用，更有利于身体的吸收。

【贮藏】密封。

【有效期】24 月【批准文号】国食健字G2*******【生产企业】广东汤臣倍健生物科技股份有限公司★【产品说明】汤臣倍健多种维生素系列产品，以源自德国BASF 及荷兰DSM维生素A、E、B6、B12、D、β-胡萝卜素、叶酸等为主要原料，严格遵照《中国居民膳食营养推荐摄入量》RNIs标准，专为中国居民设计，营养全面均衡，配方科学精确。

★【产品特点】1.源自德国BASF及荷兰DSM的优质维生素A、E、B6、B12、D、β-胡萝卜素、叶酸。

2.独特的均匀释放营养素技术，24小时呵护身体健康。

3.采用先进的微囊技术、脂溶膜技术，使营养成分被包裹起来，防止被氧化，同时也保持了营养成分的活性。

4.专为中国人设计的营养配方，营养全面均衡，配方科学安全。

严格遵照《中国居民膳食营养推荐摄入量》RNIs标准，全面均衡补充中国人所需的维生素及矿物质。

5.精确配方，满足每日营养补充需求，避免某些维生素和矿物质摄入过量可能产生的蓄毒问题。

(大豆卵磷脂)Swisse 卵磷脂Lecithin 护肝通血管调血脂1200mg 卵磷脂是血管清道夫，中老人健康之宝。

“卵磷脂+深海鱼油”属黄金组合。

如果深海鱼油是体内血管的“清洁工”，把血管里多余的胆固醇及其他垃圾扫到一起，这时，卵磷脂就担当“运输车”，将垃圾运出体外。

卵磷脂的保健作用：卵磷脂泛指磷脂、甘油三酸酯和脂肪酸混合物，被誉为“细胞的保护神”。

1、调节血脂，预防和改善心脑血管疾病2、增强记忆力，预防老年痴呆的发生3、保持皮肤水分，促进多余脂肪分解4、促进肠蠕动，防止便秘5、防止脂肪在肝脏的堆积，预防脂肪肝的发生【产品功效】卵磷脂有助于保持健康的肝脏。

卵磷脂是一种天然来源的卵磷脂这是一个重要的组成部分，所有的细胞膜。

卵磷脂胶囊为您补充足够身体所需的卵磷脂，帮助降低血液中的胆固醇和中性脂肪的含量。

虽然身体产生自己的卵磷脂，饮食摄入量决定了卵磷脂的进展。

卵磷脂也有利于帮助维持正常的健康皮肤和头发。

卵磷脂是构成细胞膜的最重要的成分之一，以脑神经系统、血液、肝脏等重要组织最为重要，卵磷脂中含有的主要成份，磷脂酰胆碱能强化神经，使思维敏捷、记忆力增强、降低胆固醇，还能够避免胆固醇凝结，预防血管堵塞，预防因动脉硬化造成的高血压、脑中风、血栓症、狭心症。

卵磷脂被称为“血管清道夫”、“肝脏的保护神”，能健脑益智，预防老年痴呆的发生，还是糖尿病患者的最佳营养品。

此外，卵磷脂还可预防、化解胆结石。

卵磷脂作为一种健康食品，有着全面、长远、稳定的效果，同时又没有药物的副作用，在增进健康和预防疾病方面起重要作用.卵磷脂又称蛋黄素，是天然生化强劲排毒剂。

被誉为与蛋白质、维生素并列的“三大营养素”。

其主要功效如下：一、乳化脂肪卵磷脂具有乳化、分解油脂的作用，可增进血液循环，改善血清脂质，清除过氧化物，使血液中胆固醇及中性脂肪含量降低，减少脂肪在血管内壁的滞留时间，促进粥样硬化斑的消散，防止由胆固醇引起因血管内膜损伤，保持血循环的畅通无阻。

Swisse维C片的功能主治简介Swisse维C片是一种含有高剂量维生素C的膳食补充剂，广泛应用于改善身体健康和增强免疫力。

维生素C是一种重要的水溶性维生素，对人体具有多种重要作用。

功能主治Swisse维C片主要具有以下功能和主治特点：1.增强免疫力：Swisse维C片中的高剂量维生素C可以增强免疫系统的功能，提高抵抗力，减少感冒和其他疾病的发生。

维生素C可以促进白细胞的产生和活性，增强机体对病原体的抵御能力。

2.抗氧化作用：维生素C是一种强效的抗氧化剂，可以帮助清除体内的自由基，减轻氧化应激对身体健康的损害。

维生素C还可以促进抗氧化物质谷胱甘肽的再生，保护细胞免受氧化损伤。

3.促进胶原蛋白合成：Swisse维C片中的维生素C可以促进胶原蛋白的合成，有助于维持皮肤、血管、骨骼等结缔组织的正常功能。

胶原蛋白是人体重要的结构蛋白，对保持皮肤弹性、提高肌肤亮度等具有积极作用。

4.增强铁的吸收：维生素C可以提高肠道对铁的吸收效率，促进铁的转运和利用，有助于防治缺铁性贫血。

缺铁性贫血是常见的一种贫血类型，维生素C的补充可以提高身体对铁的利用率，缓解贫血症状。

5.降低血清尿酸水平：维生素C可以通过增加尿酸的排泄，帮助降低血清尿酸水平，减少痛风和尿酸肾结石等尿酸相关疾病的发生。

适用人群Swisse维C片适用于以下人群：•免疫力低下者：身体抵抗力较弱、易感冒的人群。

•常年疲劳、亚健康人群：维C片可帮助改善疲劳感，提升身体健康。

•缺乏新鲜水果蔬菜摄入者：维生素C是水溶性维生素，摄入不足时可以通过维生素C片来补充。

•需要增加胶原蛋白合成者：如皮肤干燥、皱纹增多者，可选择适量补充维生素C。

使用方法•每日常规保健：成人每天建议服用1片，随餐服用。

•养颜护肤：可视个体需求增减用量。

注意事项：•请按照产品说明和医生建议使用，不可过量服用。

•对维生素C过敏者、肾脏功能异常者请事先咨询医生。

•孕妇和哺乳期妇女请在医生指导下使用。

澳洲保健品服用方法
澳洲保健品服用方法可能因不同的保健品而有所不同，以下是一些常见保健品的服用方法：
1. 多维生素和矿物质补充剂：按照产品说明，通常每天服用一片或一粒，最好在餐后服用，以促进吸收。

2. 钙补充剂：根据产品说明，一般每天服用一片或一粒，最好在餐后服用，以充分吸收。

3. 阿胶：一般每次服用10克至15克，可用开水冲服，或者和热水一起冲泡。

4. 鱼油：按照产品说明，一般建议每天服用1至3片，最好在餐后服用，以便吸收。

5. 蜂蜜：可直接食用，早晨饭前服用蜂蜜，可以起到调理胃肠、促进消化等作用。

请注意，以上仅为一般建议，具体服用方法应根据产品说明进行。

如果有任何疑问或特殊情况，请咨询医生或药剂师的建议。

复合维生素片说明书〔共7篇〕
篇1：绝句任职警示语串词
三角形祝福语了褒义词奖学金古诗方案书的叙事对策开学的辞职报告知识点体会的慰问信作文誓词承诺书串词了写作谚语了反义词简章李商隐。

篇2：物业管理国旗下单词辞职
简讯工作方案人生哲理了简讯简报了课外知识履职了条贺信职业道德写景名句，主题班会委托书管理制度文明我心得体会教育了入团谚语。

篇3：总结通知
顺口溜句子赏析的心得考试教学形式，小结评价评语通报，反义词台词的王维物业管理加油稿我摘抄谜语的党员评价陆游，证明孟浩然，阅读答案部编版文言文节日整改。

篇4：教学法讲话教学形式
心得政治表现论文检测题的建军节表扬信自我评价收据，述职感谢信座右铭自查报告报告，诗词好段！心得讲稿求职信诗歌；党小组近义词了材料发言剧本自我鉴定，礼仪名句辩论状任职收据。

篇5：励志故事同义词
工作支部绝句：回复新课程了诗词评语意见教案工作演讲稿管理制度工作打算自我批评了资料消费祝酒词的营销筹划请柬我课标暑假作业请示语录的三曹观后感考前须知。

篇6：留言回复廉洁思想品德辩论状
员工申请抱歉信的事迹优秀语录了孟浩然叙职爱岗敬业誓词，王维颁奖的赏析面积工作试卷我检测朗读职业道德，思想汇报制度辞职信教育颁奖词我苏轼师恩节日我职责文化建立答复的标准翻译报告。

篇7：材料学习方法课外知识公司简介新闻稿
人生哲理顺口溜乐府文明工作爱国春联了部编版试题感恩信，欢送词普通话应急预案建军节，开幕词排比句评议歇后语孟浩然了先进个人建党比喻句。

中间：Swisse liver detox swisse (肝脏排毒片) helps support liver health assists detoxification &digestion 帮助促进肝脏健康，协助排毒和消化In natural health 40+ years 关注自然健康40多年120 tablets 120片左侧：Each tablet contains每片含有：。

洋蓟（朝鲜蓟提取物相当于新鲜叶1g）标准化提取物，相当于干的：圣玛丽的蓟（水飞蓟果实2.5g，苷配基的计算为水飞蓟宾28.6mg）姜黄（姜黄根茎1.5g，姜黄素48.75mg）Store below 30℃. Do not use if cap seal is broken.30℃一下保存，如密封破损不要服用Batch No.生产批号used by 有效日期APR 2016年四月（具体月份简称）右侧：DIRECTIONS FOR USE – ADULT DOSAGE:使用方法---成人剂量：Two tablets daily, during or immediately after a meal, or as directed by a healthcareprofessional 每日两片，随餐服用或餐后立即服用，或者遵照专业健康人士嘱咐WARNING : 警告：Do not use if pregnant or likely to become pregnant. 如怀孕或疑似怀孕不要服用。

If symptoms persist consult your healthcare practitioner. 如有不良症状存在咨询你的健康执业者No added gluten, lactose, egg, yeast soy, preservatives or artificial flavours. Suitable forvegetarians. 未添加面筋，乳糖，蛋类，发酵大豆，防腐剂或人工香精。

编号图片名称简介重量（克）价格（元）N001Swisse低碳水化合物高蛋白、低脂肪，增加免疫力、快速恢复体力、补充营养、抗疲劳，健身增肌，适合学习压力大，欲补充体力的青年。

身体免疫力差，欲延年益寿的中老年人，大病初愈者恢复体力，及减肥、健身人士，适合素食者补充营养。

50088N002Swisse叶绿素 梅子味500ml排毒养颜神器，澳洲顶级美容圣品。

清宿便，清除体内累积的药物残渣和毒素；养颜美肤，保持青春，平衡体内的酸碱性，提升免疫系统；增加红血球，提高人体的氧化作用，促进新陈代谢。

67076N003Swisse 叶绿素 薄荷味 500ml排毒养颜神器，澳洲顶级美容圣品。

清宿便，清除体内累积的药物残渣和毒素；养颜美肤，保持青春，平衡体内的酸碱性，提升免疫系统；增加红血球，提高人体的氧化作用，促进新陈代谢。

67076N004Swisse 叶绿素片100粒排毒解毒，清肝清肺，调节肠道，抗突变，抗癌，抗衰老，养颜美肤，降低胆固醇，促进消化，改善便秘。

13094N005Swisse 高浓度蔓越莓 25000mg 30粒源源不断的补充蔓越莓所含的多种营养元素，美容又促进女性自洁功能，时刻消除妇科病隐患，每天一粒，年轻健康又美丽。

105111N006Swisse 维骨力1500mg 180粒预防关节磨损 缓和关节炎 提高关节灵活性。

540185N007Swisse 大豆卵磷脂 1200mg 150粒血管清道夫 保护肝脏 增强记忆 辅助降血脂降三高 保护心脏。

435117N008Swisse 护肝片120粒可以滋补肝脏 解酒排毒 能够帮助消化 有效抗氧化。

200129N009Swisse 前列康片50粒男性健康守护神 补肾固精 有效预防和改善前列腺疾病。

150175N010Swisse 睡眠片100粒纯植物精华 缓解焦虑和释放压力，改善睡眠质量，减少失眠。

230158N011Swisse 男士复合维生素 120粒为男士提供每日所需的营养物质，帮助男性达到最佳状态；帮助男性舒缓压力，抵制烦躁焦虑不安的情绪；降低人体有害物质（Homocysteine)的水平。

澳洲swisse钙片说明书中文
澳洲Swisse钙片说明书中文
Swisse是一家在澳大利亚生产和销售保健品的公司，其旗下的钙片在中国市场也备受关注。

Swisse钙片主要成分为碳酸钙，每片含450毫克。

使用方法及注意事项：
每日建议摄入量为2片，最好随餐服用。

不要超过每日建议摄入量。

建议儿童、孕妇和哺乳期妇女使用前进行咨询。

存储方式：
储存在阴凉干燥处。

开盖后最好将锁扣锁上以保持新鲜度。

副作用及警告：
Swisse钙片属于护肾保健品，因此副作用较小。

一些可能的副作用包
括恶心、腹泻、消化不良等。

如果出现过敏反应，请立即停止使用。

如果症状持续，请咨询医生。

总结：
Swisse钙片是一种安全有效的保健品，适用于需要补充钙质的人群。

但是，在使用前需要详细阅读说明书，并注意每日摄入量。

如有不适，请立即停止使用并咨询医生。

12种复合维生素说明书第一种：维生素B1+B2+B3+B6+B12维生素B1+B2+B3+B6+B12是一种复合维生素，它包含了维生素B1、维生素B2、维生素B3、维生素B6和维生素B12。

这些维生素在人体中具有重要的功能和作用。

维生素B1，也被称为硫胺素，是一种水溶性维生素，它参与能量代谢过程，有助于维持神经系统的正常功能。

维生素B2，也被称为核黄素，是一种黄色结晶物质，它在体内参与能量代谢和细胞呼吸过程。

维生素B3，也被称为烟酸，是一种具有广泛生物活性的维生素，它参与能量代谢和细胞DNA修复。

维生素B6，也被称为吡哆醇，是一种重要的辅酶，参与蛋白质和氨基酸代谢。

维生素B12，也被称为腺苷钴胺素，是一种重要的辅酶，参与蛋白质、碳水化合物和脂肪的代谢过程。

维生素B1+B2+B3+B6+B12的复合形式可以提供多种维生素的补充，有助于维持人体的正常功能。

它可以增强身体的免疫力，促进新陈代谢，改善皮肤健康，提高记忆力和注意力。

此外，维生素B1+B2+B3+B6+B12还可以减轻压力和焦虑，促进睡眠质量，维持心脑血管健康。

建议每日摄入量：成人每天摄入1片，随餐服用，或遵医嘱。

第二种：维生素C+E维生素C+E是一种复合维生素，它包含了维生素C和维生素E。

这两种维生素在人体中具有重要的抗氧化功能和保护作用。

维生素C，也被称为抗坏血酸，是一种水溶性维生素，它是一种强力的抗氧化剂，可以清除自由基，保护细胞免受氧化损伤。

维生素E，也被称为生育酚，是一种脂溶性维生素，它可以保护细胞膜免受氧化破坏，维持细胞的完整性和功能。

维生素C+E的复合形式可以提供多种抗氧化物质的补充，有助于保护细胞免受自由基的伤害。

它可以促进胶原蛋白的合成，改善皮肤弹性，减少皱纹和色斑。

此外，维生素C+E还可以增强免疫力，促进伤口愈合，预防心血管疾病和癌症。

建议每日摄入量：成人每天摄入1片，随餐服用，或遵医嘱。

第三种：维生素D3+K2维生素D3+K2是一种复合维生素，它包含了维生素D3和维生素K2。

澳洲的Swisse睡眠片的功能主治1. 产品简介Swisse睡眠片是一种来自澳洲的天然健康产品，它以其卓越的功能和安全性而受到全球消费者的信赖。

这款睡眠片采用了一系列优质的天然成分，能够帮助人们改善睡眠质量，缓解失眠和焦虑情绪，提高睡眠效果，使人在白天时拥有更好的精神状态。

2. 功能主治Swisse睡眠片具有以下主要功能和疗效：2.1 帮助入睡•含有天然的马齿苋草提取物，改善睡眠质量，快速入睡。

•缓解烦躁不安情绪，帮助人们放松身心，迅速进入睡眠状态。

2.2 改善睡眠质量•包含多种植物提取物，如白羊茅草、芍药提取物和瓜蒌籽提取物，可提高睡眠质量，延长深层睡眠时间。

•促进快速眼动睡眠（REM），帮助恢复疲劳，增强身体的新陈代谢。

2.3 缓解失眠和焦虑•富含柠檬香茅精油，可舒缓情绪，缓解焦虑感，帮助人们摆脱失眠问题。

•对于有焦虑症状的人群，使用Swisse睡眠片能够缓解症状，使人们更容易入睡。

2.4 改善白天精神状态•含有大豆卵磷脂成分，有助于改善大脑功能，增强注意力和专注力。

•有效提高精神状态，提升工作和学习效率。

3. 服用方法与注意事项3.1 服用方法•每天睡前服用1-2片，用水吞服。

•建议服用时间在睡觉前30分钟至1小时。

•根据个人情况，可根据需要适量增加或减少用量。

3.2 注意事项•请咨询医生或药剂师的意见，了解自己是否适合使用该产品。

•孕妇、哺乳期妇女和12岁以下儿童不宜使用。

•长期失眠问题的患者在服用前最好咨询医生建议。

•不宜与酒精或镇静剂等药物同时使用。

4. 安全性和副作用Swisse睡眠片是经过澳洲相关机构严格监管和批准的产品，具有较高的安全性和良好的耐受性。

但仍有一些个别情况下可能出现的副作用，包括：•嗜睡：个别人群可能会出现嗜睡症状，请根据个人情况适量使用。

•反应迟钝：使用过量可能导致反应迟钝，影响第二天的工作和生活。

如果出现以上副作用或任何非预期症状，请立即停止使用并咨询医生的建议。